You are viewing the correction.
VIEW THE CORRECTED ARTICLEIn the article entitled “Antiplatelet Therapy for Secondary Prevention of Noncardioembolic Ischemic Stroke: A Critical Review” by O’Donnell et al,1 the authors report two errors. First, in Table 3, under Cilostazol’s Serious Vascular Event Risk Reduction (95% CI) column, the values should be “(0.41–0.91)” instead of “(0.41–0.01).” Second, on page 1641, the reference number of the “Efficacy” category under the “Cilostazol Versus Control” Section should be “41” instead of “42.”
The authors regret these errors.
The corrected version can be viewed online at http://stroke.ahajournals.org.
1 [Correction for Vol 39, Number 5, May 2008. Pages 1638–1646.]
Information & Authors
Information
Published In
On the cover: World Stroke Day logo courtesy of the Lawson Research Institute, London, Ontario, Canada.
Copyright
© 2008.
History
Published online: 1 September 2008
Published in print: 1 September 2008
Authors
Metrics & Citations
Metrics
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
Purchase this article to access the full text.
eLetters(0)
eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.
Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.